Valeant settles the R&O lawsuit that touched off its specialty pharmacy woes

Valeant's ($VRX) relationship with now-dissolved specialty pharmacy Philidor may be the one that has drawn the most scrutiny from short sellers, investors and regulators. But it was litigation from another specialty pharmacy, R&O, that opened up the controversy in the first place. Now, Valeant has settled that R&O lawsuit, it said Wednesday--but that hardly means it's out of the woods. As the Canadian drugmaker recently disclosed, the SEC is investigating, and sources have told The Wall Street Journal that its Philidor connections are the subject of the probe. Release | More

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Johnson & Johnson is chasing giants in its play for psoriatic arthritis with Tremfya. Strong data could help the newcomer convince the FDA.

Besting AbbVie's megablockbuster Humira is no laughing matter, but now Eli Lilly's Taltz has doubled up on head-to-head wins.